Mirum Net Working Capital from 2010 to 2024

MIRM Stock  USD 46.65  1.50  3.32%   
Mirum Pharmaceuticals Net Working Capital yearly trend continues to be very stable with very little volatility. Net Working Capital is likely to drop to about 169.3 M. During the period from 2010 to 2024, Mirum Pharmaceuticals Net Working Capital quarterly data regression pattern had sample variance of 5934.5 T and median of  49,526,000. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
300.5 M
Current Value
169.3 M
Quarterly Volatility
77 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Mirum Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mirum Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 12.7 M, Discontinued Operations of 0.0 or Interest Expense of 9.4 M, as well as many indicators such as Price To Sales Ratio of 6.15, Dividend Yield of 0.0 or PTB Ratio of 5.1. Mirum financial statements analysis is a perfect complement when working with Mirum Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Mirum Pharmaceuticals Correlation against competitors.
To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.

Latest Mirum Pharmaceuticals' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Mirum Pharmaceuticals over the last few years. It is Mirum Pharmaceuticals' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mirum Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Mirum Net Working Capital Regression Statistics

Arithmetic Mean99,281,167
Geometric Mean79,638,179
Coefficient Of Variation77.59
Mean Deviation59,706,200
Median49,526,000
Standard Deviation77,035,625
Sample Variance5934.5T
Range251M
R-Value0.75
Mean Square Error2749.5T
R-Squared0.57
Significance0
Slope13,002,638
Total Sum of Squares83082.8T

Mirum Net Working Capital History

2024169.3 M
2023300.5 M
2022125.5 M
2021124 M
2020217.9 M
2019106.3 M

About Mirum Pharmaceuticals Financial Statements

Mirum Pharmaceuticals investors utilize fundamental indicators, such as Net Working Capital, to predict how Mirum Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Working Capital300.5 M169.3 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Mirum Pharmaceuticals is a strong investment it is important to analyze Mirum Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Mirum Pharmaceuticals' future performance. For an informed investment choice regarding Mirum Stock, refer to the following important reports:
Check out the analysis of Mirum Pharmaceuticals Correlation against competitors.
To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.08)
Revenue Per Share
6.513
Quarterly Revenue Growth
0.894
Return On Assets
(0.09)
Return On Equity
(0.40)
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.